How to Prove Your Ozempic and Wegovy Lawsuit?
To prove your Ozempic or Wegovy lawsuit, gather your prescription records, medical reports detailing side effects, and any related expenses. Keep a detailed log of symptoms and treatments. Partner with an experienced drug injury lawyer to build your case and hold the manufacturer accountable.
Have you or someone close to you suffered serious side effects from Ozempic or Wegovy? Uptown Injury Law, PLLC, is ready to fight for your rights. Call us now at 917-540-8728 for a free case evaluation and get the compensation you deserve.
Recent Updates in Ozempic and Wegovy Lawsuit
The Ozempic and Wegovy lawsuit continues to gain momentum, with significant updates emerging since October 2024. Here are the latest updates:
A New Case Adds Weight to the MDL – November 13, 2024
A Tennessee plaintiff alleged severe gastrointestinal injuries, including gastroparesis, due to Ozempic and Wegovy use. She was prescribed the medications in 2022 and experienced persistent symptoms, which were confirmed by a gastric emptying study in 2023.
Consequently, the lawsuit accuses Novo Nordisk of failing to adequately warn users and healthcare providers of these risks.
Novo Nordisk Blamed for Downplaying Risks – November 12, 2024
Plaintiffs now claim that Novo Nordisk minimized the risks of gastroparesis in its marketing campaigns. Even as evidence showed the impact of these drugs on stomach motility, the company allegedly resisted updating its warning labels. As a result, this issue has become a focal point in the litigation.
FDA Highlights Surgical Risks – November 7, 2024
The FDA warned about pulmonary aspiration risks associated with GLP-1 drugs, including Ozempic and Wegovy. Patients are urged to disclose GLP-1 drug use before surgery to avoid complications.
New Cases Added to Ozempic Multidistrict Litigation – November 1, 2024
The MDL added 131 new cases in October, bringing the total to 1,221. Lawyers are now prioritizing well-documented gastroparesis cases.
Main Reasons Behind Legal Claims Against Semaglutide Drugs
Individuals are filing Ozempic lawsuits, claiming that semaglutide drugs can lead to severe health complications. Plaintiffs allege that the pharmaceutical companies concealed or downplayed these side effects. The health complications suffered by patients include the following:
- Severe gastrointestinal issues, such as gastroparesis, stomach paralysis, ileus, and intestinal blockages
- Pancreatitis
- Suicidal ideation, with over 150 reports under review by the European Medicines Agency
- Gallbladder diseases, including gallstones and gallbladder inflammation, as confirmed in GLP-1 RA studies
- Severe vomiting, stomach pain, and nausea causing malnutrition and other secondary health conditions
Concerns have also been raised about Novo Nordisk’s aggressive marketing strategies. The company invested more than $1 million in promoting Ozempic, leading plaintiffs to claim that profits were prioritized over patient safety.
Furthermore, these lawsuits particularly highlight the promotion of off-label uses, such as long-term weight management for non-diabetic patients—practices that have not received full FDA approval and lack adequate warnings.
If you’ve experienced severe side effects from semaglutide drugs, contact Uptown Injury Law, PLLC, at 917-540-8728. Our experienced attorneys are here to help you file your claim within New York’s statute of limitations and seek the justice you deserve.
FDA and Scientific Studies on Ozempic and Wegovy
The FDA has documented hundreds of adverse event reports linked to both compounded and FDA-approved versions of semaglutide drugs like Ozempic and Wegovy. As of August 31, 2024, there have been 346 reports for compounded semaglutide and 136 for compounded tirzepatide.
These FDA-approved medications are widely used to treat obesity and diabetes, but recent studies highlight severe gastrointestinal issues and other health issues. Scientific research provides further evidence of these serious health complications:
Jensterle et al. (2023): Semaglutide Delays Gastric Emptying
In clinical trials of weight loss drugs in 20 obese women, semaglutide increased gastric content retention by up to 30% over 4 hours. Compared to a placebo, it significantly slowed gastric emptying.
Kalas et al. (2023): GLP-1 RA Use in Diabetics with Delayed Gastric Emptying
A chart review revealed that 24% of diabetic patients with delayed gastric emptying had been taking GLP-1 RAs like semaglutide. This finding suggests a strong correlation between the use of these medications and slowed stomach motility.
Klein & Hobai (2023): Semaglutide and Pulmonary Aspiration
This case report detailed a patient taking semaglutide, a diabetes drug, experiencing retained stomach contents despite fasting. This led to intraoperative pulmonary aspiration, a severe health complication.
Preda et al (2023): Gastroparesis and Bezoar Formation
Among 100 bariatric surgery patients, 4 out of 23 using GLP-1 RAs developed bezoars, compared to none in the non-GLP-1 RA group. Symptoms resolved 1–3 weeks after stopping the prescription drug.
Sherwin et al. (2023): Residual Gastric Solids After Fasting
A study of 20 participants found that 70–90% of semaglutide users had residual solids visible on gastric ultrasound after 8 hours of fasting.
Who Is the Manufacturer of Ozempic and Wegovy?
Novo Nordisk is the exclusive manufacturer of FDA-approved semaglutide drugs such as Ozempic, Wegovy, and Rybelsus. Having a $300 billion value, the company is renowned for its diabetes and weight loss drugs.
Currently, the company is the target of lawsuits alleging it failed to adequately warn consumers about the severe side effects of Ozempic and Wegovy. These include gastroparesis, intestinal blockages, and other serious health complications.
Additionally, the plaintiffs argue that Novo Nordisk prioritized profits over patient safety by concealing critical warnings from its drug labels.
However, this isn’t the first time Novo Nordisk has been subject to legal scrutiny. Previously, the company settled for $1.1 million and resolved additional claims totaling $58 million after failing to comply with a mandatory FDA risk evaluation program.
Eligibility Criteria to File an Ozempic and Wegovy Lawsuit
To qualify for filing an Ozempic or Wegovy lawsuit, you may need to meet the following criteria:
- You were prescribed Ozempic or the weight loss drug Wegovy.
- Experienced a serious health complication within 30 days of use
- 75 years old or younger when you began taking the medication
- Have medical records confirming the diagnosis (Gastroparesis or similar conditions)
- File within your state’s legal deadline.
Consulting with an experienced Ozempic and Wegovy lawyer is crucial to verify your eligibility and build a strong case. At Uptown Injury Law, PLLC, we specialize in pharmaceutical lawsuits and have consistently secured maximum compensation for our clients.
Our legal team will diligently gather detailed medical records, prove your claim with expert analysis, and manage all negotiations for you. To begin with a free consultation, contact us today at 917-540-8728.
Evidence To Collect Before Filing Your Semaglutide Lawsuit
When filing a semaglutide lawsuit, it’s necessary to gather strong evidence. Proper documentation strengthens your case and establishes a link between the medication and your health complications.
You must collect the following evidence before filing the claim:
- Medical records
- Prescription information
- Documentation of ER visits or hospitalizations
- Symptom journal
- Work and financial records
- Expert medical opinions
A skilled Wegovy lawyer ensures that all necessary evidence is collected and presented effectively. At Uptown Injury Law, PLLC, our experienced attorneys will help you gather essential documents and leverage our resources to consult with top medical experts, building an undeniable case on your behalf.
How to File an Ozempic and Wegovy Lawsuit?
To begin your Ozempic lawsuit, contact an experienced attorney for a free case consultation. During this initial meeting, your lawyer will evaluate your eligibility for compensation based on your medical history, side effects, and other documentation.
Once your eligibility is confirmed, your lawyer will collect medical records, prescription details, hospital reports, expert testimony, and witness statements. This evidence is important to strengthen your claim and establish a clear connection between the drug and your health complications.
With all the necessary evidence compiled, your attorney will then formally file your claim, adhering to the New York statute of limitations, and manage the entire legal process.
After the lawsuit is filed, your attorney will negotiate a fair settlement with the drug manufacturers. If negotiations do not result in a satisfactory outcome, your attorney will take the case to trial, advocating for your rights and seeking justice in court.
Statute of Limitations for Ozempic and Wegovy Claims
In New York, the statute of limitations for filing an Ozempic and Wegovy claim is three years from the date of injury or the discovery of harm. This timeframe ensures you can seek compensation for medical expenses, lost wages, and other damages.
However, missing the statute of limitations deadline can result in losing your right to take legal action. Deadlines may vary depending on the jurisdiction, and there could be exceptions based on the specifics of your case, such as delayed diagnoses or cases involving minors.
Is There a Class Action Lawsuit Against GLP- 1 RA Drugs?
Currently, there is no class action lawsuit for GLP-1 receptor agonists (GLP-1 RAs) like Ozempic and Wegovy. However, these drugs are a part of an ongoing multidistrict litigation (MDL) that consolidates individual lawsuits against manufacturers such as Novo Nordisk and Eli Lilly.
Established in February 2024 by the Judicial Panel on Multidistrict Litigation (JPML), the MDL is being heard in the Eastern District of Pennsylvania federal court. This MDL includes claims involving GLP-1 RA drugs, including Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro.
Ozempic and Wegovy Lawsuit Settlement Amounts
The settlement amountfor Ozempic and Wegovy lawsuit range from $400,000 to $1 million. However, the actual amount will depend on the specifics of each case. Several factors can determine the final settlement amount, such as:
- The severity of the injuries or damages
- The cost of past, ongoing, and future medical treatment
- Impact on your quality of life
- Lost wages and decreased ability to work
- Emotional distress, pain, and suffering
How Long Does an Ozempic Lawsuit Typically Take To Resolve?
The time it takes to resolve an Ozempic lawsuit can vary significantly, from a few weeks to several years. The timeline may depend on the complexity of your case and other factors, such as:
- Strength of evidence
- Type of injury
- Severity of losses
- The defendant’s willingness to settle
How Much Does It Cost to Hire an Ozempic Lawyer?
Hiring an Ozempic lawyer comes at no out-of-pocket cost, as most attorneys operate on a contingency fee structure. This means they only get payment if they successfully win your case.
Typically, their fee is a percentage of your settlement or payout, ranging from 20% to 40%, depending on the complexity of your claim.
This fee arrangement is beneficial because it allows you to pursue justice and compensation without any initial financial burden. Furthermore, your attorney will handle all aspects of your case—from gathering evidence to negotiating—allowing you to focus on your health and recovery.
Why Choose Us for Your Ozempic or Wegovy Case?
If you’ve experienced severe side effects from Ozempic or Wegovy, Uptown Injury Law PLLC offers the legal expertise and dedication you need. With a history of multi-million dollar settlements for injured clients across New York, we have the experience to hold drug manufacturers accountable.
Here’s why we’re trusted by clients statewide:
- Proven Track Record: Over 15 years of success in pharmaceutical litigation.
- No-Win, No-Fee Policy: You pay nothing unless we win your case.
- Nationally Recognized Attorneys: Named among National Trial Lawyers Top 40 Under 40 and featured in Super Lawyers.
- Client-Focused Service: Personalized representation with clear, responsive communication.
Don’t wait—New York’s statute of limitations restricts the time you have to file a claim. Call us today at 917-540-8728 for your free case review, and let us help you pursue the compensation and justice you deserve.
FAQs
Is Ozempic Gastroparesis Permanent?
Ozempic-induced gastroparesis is typically temporary. Symptoms often improve once you stop or adjust the medication. However, individual experiences differ, and persistent symptoms may need medical attention.
Consult your healthcare provider to assess your condition and explore personalized treatment options to address your needs effectively.
What Is the Current Status of the Ozempic Lawsuit?
As of November 2024, the Ozempic litigation is in the pretrial phase, with ongoing discovery and procedural developments. Moreover, the number of cases has grown significantly, with 1,221 personal injury lawsuits filed as of November 2024.
In July 2024, investigations expanded to include allegations such as vision loss associated with semaglutide drugs like Ozempic.
Is Wegovy Safer Than Ozempic?
The safety profiles of both Ozempic and Wegovy are similar, as they share the same active ingredient. However, safety depends on factors such as your medical history, dosage, and how your body responds to treatment.
What Are the Long-Term Side Effects of Wegovy?
The long-term side effects of Wegovy may include gastrointestinal issues such as severe nausea, constipation, diarrhea, and vomiting. Some users have also reported gallbladder problems, including gallstones and an increased risk of pancreatitis.
Rarely, Wegovy may lead to thyroid tumors, including medullary thyroid carcinoma, based on animal studies.
What Is the New Warning on Ozempic?
The U.S. Food and Drug Administration (FDA) has updated Ozempic’s label to include a warning about the risk of intestinal blockages, specifically ileus. This update follows reports of patients experiencing delayed gastric emptying while using Ozempic.
Which Weight Loss Drugs Are a Part of the Wegovy Lawsuit?
The Wegovy lawsuit includes weight loss and diabetes drugs such as Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro. These medications, all part of the GLP-1 receptor agonist class, are being scrutinized for severe side effects like gastroparesis, intestinal blockages, and other health complications.
